Interstitial lung disease (ILD) is the leading cause of death
in patients with systemic sclerosis (SSc). Randomized controlled trials have favored the use of cyclophosphamide (CYC) for treating SSc-ILD3,4,5. Compared with placebo, 1 year of CYC improved lung function in patients with SSc-ILD in Scleroderma Lung Study (SLS) I3
SSc is a complex rheumatoid disease characterized by autoimmunity, fibrosis, and vasculopathy. Mouse models provide powerful research tools for exploring the pathogenesis of human diseases
Systemic Sclerosis (SSc) is a rare autoimmune disease that is characterized by progressive skin fibrosis, an obliteration of the microvasculature and an exaggerated extracellular matrix deposition,
which lead to multisystemic dysfunction.
The objective of this article was to establish the clinical course of interstitial lung disease (ILD) in scleroderma related to the presence of anti-PM/Scl antibody compared with anti-Scl-70 in a Spanish cohort. Furthermore, no study has thoroughly investigated the outcome of pulmonary function test in the first group of patients.
The increased incidence of malignancies in systemic sclerosis (SSc) accounts for about 10 percent of the mortality in this disease. In 1979, a study showed that 4 percent of SSc patients developed cancer, most commonly breast cancer, followed by lymphoma/leukemia, gastrointestinal malignancy and cervical cancer. Subsequent studies demonstrated high standardized incidence ratios (SIR) of overall cancer, lung, bladder and liver cancer, and hematologic malignancies.